GCM
NKTR icon

Gladius Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Gladius Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,276
Closed -$19.6K – 424
2023
Q2 		$19.6K Buy
+2,276
New +$24.3K ﹤0.01% 306

Other funds holding NKTR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Gladius Capital Management's NKTR Position: Q3 2023 in Review

Gladius Capital Management sold out of Nektar Therapeutics (NKTR) in Q3 2023, closing a stake of 2,276 shares — an estimated $19.6K sold.

Gladius Capital Management first reported a position in NKTR in Q2 2023 and held it in 1 quarter. The position peaked at $19.6K in Q2 2023. 138 funds tracked by Wall St. Rank hold NKTR as of Q3 2023.

  • Gladius Capital Management reported no remaining Nektar Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Gladius Capital Management sold 2,276 Nektar Therapeutics shares in Q3 2023, an estimated $19.6K.
  • Gladius Capital Management first reported a position in Nektar Therapeutics in Q2 2023 and held it in 1 quarter.
  • Gladius Capital Management's Nektar Therapeutics position peaked at $19.6K in Q2 2023.
  • 138 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2023.

Based on Gladius Capital Management's 13F filing for Q3 2023, filed 10 Oct 2023.